5-amino-1mq half-life purity peptide ideal for laboratory research and development 5-Amino-1MQ Vial (5MG)

The largest published trial (METAOD006/OPTIONS) randomized 502 adults with obesity to AOD-9604 or placebo for 24 weeks alongside a diet and exercise program

The 60/40 approach places 60 percent of the dose in the morning (fasted) and 40 percent in the evening (before dinner or before bed)

While AOD-9604 is not FDA-approved as a prescription drug, it has received GRAS (Generally Recognized as Safe) status, indicating low toxicity and a good safety profile

Preclinical studies demonstrated that AOD-9604 was generally safe after chronic oral application in rats and cynomolgus monkeys, with no genotoxic concerns identified

Now you're looking at peptides